Hill-Rom Holdings, Inc. (NYSE:HRC) – Equities research analysts at KeyCorp increased their FY2019 EPS estimates for shares of Hill-Rom in a report released on Wednesday. KeyCorp analyst M. Mishan now forecasts that the medical technology company will post earnings of $5.08 per share for the year, up from their previous estimate of $4.70. KeyCorp currently has a “Buy” rating and a $97.00 target price on the stock.
HRC has been the subject of several other research reports. ValuEngine downgraded shares of Hill-Rom from a “buy” rating to a “hold” rating in a research note on Friday, December 1st. Zacks Investment Research downgraded shares of Hill-Rom from a “buy” rating to a “hold” rating in a research note on Tuesday, January 9th. Raymond James Financial upgraded shares of Hill-Rom from a “market perform” rating to an “outperform” rating and set a $94.00 price target for the company in a research note on Wednesday, January 3rd. Barclays boosted their target price on shares of Hill-Rom from $86.00 to $90.00 and gave the stock an “overweight” rating in a research note on Monday, November 6th. Finally, Bank of America reiterated a “hold” rating on shares of Hill-Rom in a research note on Wednesday, November 22nd. Five research analysts have rated the stock with a hold rating and six have given a buy rating to the company’s stock. The company currently has an average rating of “Buy” and a consensus price target of $95.38.
Hill-Rom (NYSE HRC) traded up $1.50 during trading hours on Friday, hitting $89.30. 512,759 shares of the company’s stock traded hands, compared to its average volume of 371,576. The firm has a market capitalization of $5,779.08, a P/E ratio of 44.87, a price-to-earnings-growth ratio of 1.55 and a beta of 1.19. The company has a current ratio of 1.77, a quick ratio of 1.34 and a debt-to-equity ratio of 1.55. Hill-Rom has a fifty-two week low of $57.18 and a fifty-two week high of $89.64.
Hill-Rom (NYSE:HRC) last posted its quarterly earnings results on Friday, November 3rd. The medical technology company reported $1.32 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $1.27 by $0.05. The business had revenue of $738.30 million during the quarter, compared to the consensus estimate of $731.10 million. Hill-Rom had a net margin of 4.87% and a return on equity of 20.27%. The company’s quarterly revenue was up 4.6% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $1.18 earnings per share.
Institutional investors and hedge funds have recently made changes to their positions in the stock. Seven Eight Capital LP purchased a new stake in Hill-Rom in the second quarter valued at $127,000. Citigroup Inc. lifted its position in Hill-Rom by 21.1% in the second quarter. Citigroup Inc. now owns 2,483 shares of the medical technology company’s stock valued at $198,000 after acquiring an additional 433 shares during the last quarter. DekaBank Deutsche Girozentrale lifted its position in Hill-Rom by 101.0% in the third quarter. DekaBank Deutsche Girozentrale now owns 2,720 shares of the medical technology company’s stock valued at $204,000 after acquiring an additional 1,367 shares during the last quarter. Fox Run Management L.L.C. purchased a new stake in Hill-Rom in the third quarter valued at $207,000. Finally, CAPROCK Group Inc. purchased a new stake in Hill-Rom in the fourth quarter valued at $211,000. 81.92% of the stock is owned by hedge funds and other institutional investors.
In related news, SVP Paul Sherwood Johnson sold 1,000 shares of the business’s stock in a transaction on Wednesday, December 13th. The shares were sold at an average price of $82.99, for a total value of $82,990.00. Following the completion of the sale, the senior vice president now directly owns 1,066 shares of the company’s stock, valued at $88,467.34. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Also, CEO John J. Greisch sold 125,241 shares of the business’s stock in a transaction on Friday, December 15th. The shares were sold at an average price of $82.59, for a total transaction of $10,343,654.19. Following the completion of the sale, the chief executive officer now directly owns 280,851 shares of the company’s stock, valued at $23,195,484.09. The disclosure for this sale can be found here. In the last quarter, insiders have sold 226,241 shares of company stock valued at $18,708,644. Insiders own 2.20% of the company’s stock.
The company also recently announced a quarterly dividend, which was paid on Friday, December 29th. Investors of record on Friday, December 15th were paid a dividend of $0.18 per share. The ex-dividend date of this dividend was Thursday, December 14th. This represents a $0.72 dividend on an annualized basis and a dividend yield of 0.81%. Hill-Rom’s payout ratio is currently 36.18%.
WARNING: “KeyCorp Weighs in on Hill-Rom Holdings, Inc.’s FY2019 Earnings (HRC)” was first published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this piece on another publication, it was copied illegally and reposted in violation of U.S. and international trademark & copyright legislation. The original version of this piece can be read at https://www.dispatchtribunal.com/2018/01/20/keycorp-weighs-in-on-hill-rom-holdings-inc-s-fy2019-earnings-hrc.html.
Hill-Rom Company Profile
Hill-Rom Holdings, Inc is a global medical technology company. The Company operates through four segments: North America Patient Support Systems, International Patient Support Systems, Front Line Care and Surgical Solutions. The Company’s products and services include Patient Support Systems, Front Line Care and Surgical Solutions.
Receive News & Ratings for Hill-Rom Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hill-Rom and related companies with MarketBeat.com's FREE daily email newsletter.